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EDITORIALS
Finally More Direct Evidence That Impulse Oscillometry Measures
Small Airway Disease
Asthma is an inﬂammatory airway disease affecting the entire
bronchial tree. Although it is now increasingly recognized that the
small airways, deﬁned as those with an internal diameter of 2 mm or
less, play an important role in asthma, it is notoriously difﬁcult to
measure small airway inﬂammation and/or dysfunction (1). The
recent multinational ATLANTIS (Assesment of Small Airways
Involvement in Asthma) study performed a variety of physiological
tests as well as computed tomography (CT) imaging in 773 patients
with asthma and 99 control individuals to investigate the role of small
airway disease (2). Small airway disease was shown to contribute
importantly to the severity of asthma assessed by GINA (Global
Initiative for Asthma) treatment step, asthma control, and history of
exacerbations (2). In ATLANTIS, the prevalence of small airway
disease varied with the physiological measure used. It was lower with
Sacin (19%) and residual volume (RV)/TLC (22%), higher with
resistance at 5 Hz (R5)2 resistance at 20 Hz (R20) (42%) and forced
expiratory ﬂow, midexpiratory phase (FEF25–75), and a decrease in
FVC during provocative concentration of methacholine, causing a
20% fall in FEV1 (PC20) (73%). This was hypothesized to be a result
of different small airway disease subtypes, depending on the location
in the bronchial tree, with Sacin and RV/TLC reﬂecting the more
peripheral airways and R52R20, FEF25–75, and decrease in FVC
during PC20 methacholine reﬂecting the small-sized to midsized
airways (2). However, the major drawback is that exactly which
compartment of the bronchial tree each of the aforementioned tests
reﬂects has never been directly investigated.
Therefore, the ﬁndings published in this issue of the Journal by
Foy and colleagues (pp. 982–991) are important (3). Based on CT
imaging data, the researchers reconstructed virtual bronchial trees
of 21 patients with asthma and 11 healthy control individuals. To
this end, centerlines of the airways were extracted up to generations
6–10, and the remainder of the conducting airways were
reconstructed computationally, thus ultimately spanning
generations 1–16, including a total of 30,000–100,000 large and
small airways (4). Using this model, the resistance for each
individual branch was calculated, and then all values were summed
up into a simulated measure of R52R20. The reliability of this
approach was conﬁrmed by the ﬁnding that the simulated
R52R20 values of these 32 subjects were signiﬁcantly associated
with actual measured R52R20 outcomes. Because this ﬁrst step
was successful, the authors then used the reconstructed lung model
to investigate what the effect of constriction of airways located in
different parts of the bronchial tree (trachea to small airways)
would be on R52R20 levels. Interestingly, constriction of the
small airways (sixth generation and further; average diameter,
,1.39 mm) consistently produced larger increases in simulated
R52R20 values than constriction of the large airways in their
model. Using data from a larger clinical asthma cohort and
adjusting for possible confounders, the authors then assessed how
changes in R52R20 would affect the severity of asthma symptoms
and demonstrated that narrowing of the small airways by more
than 40% would generate clinically important changes in asthma
control and quality of life.
The ﬁndings of Foy and colleagues are very interesting, as they
provide, for the ﬁrst time to our knowledge, direct evidence on how
R52R20 reﬂects airway narrowing in speciﬁc locations of the
bronchial tree and strengthen the notion that R52R20 is a useful
tool to measure small airway disease in asthma.
In the study by Foy and colleagues, the association between
simulated R52R20 and the actually measured values, although
statistically signiﬁcant, was relatively weak. This may have been because
the computational modeling to build the bronchial tree was imperfect
as a result of certain assumptions, such as the use of a simple constant-
phase model (5). Another possible explanation is the imprecision of the
actually measured R52R20, as the impulse oscillometry technique can
also be prone to sources of error (e.g., introduced by variations in
patient breathing and upper airway/cheek shunting) (6). Which of the
two will be the most relevant to the diagnosis and management of
small airway disease remains to be established.
This nice study with very complicated computational models is
based on actual CT measurements up to generations 6–10, and
essentially on extrapolation from there to the alveoli. The group
from Vancouver has added analysis of actual pathology specimens
from explanted lungs to further assess the smaller airways, which
could be a useful addition for the current technique as well (7, 8).
In addition, the modeled sites of constriction from trachea to small
airways could perhaps be further validated by actually imposing
constriction in patients with asthma in different parts of the
bronchial tree (e.g., with small vs. large particle size
bronchoprovocation agents) (9).
The authors have been brave to take as their primary correlate of
small airway disease asthma control and quality of life, thereby linking
small airway disease to what matters to the patient. They showed
reasonably good correlations between R52R20 and asthma control
and also showed that these parameters improve with biologics.
A great opportunity would be to replicate the ﬁndings of Foy
and colleagues in the larger ATLANTIS cohort. This makes it
possible not only to conﬁrm that simulated R52R20 is associated
with the actually measured outcome but also to assess the
respective values of simulated and actual R52R20 outcomes in
relation to a variety of other small airway measurements, as well
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as to cross-sectional and longitudinal (1-yr) follow-up data on
asthma control and exacerbation frequency. In addition, it will be
of interest to use the CT-based model to connect changes in
airway caliber in different locations of the reconstructed bronchial
tree to other small airway parameters such as multiple breath
nitrogen washout, FEF, alveolar nitric oxide, and lung
hyperinﬂation. This will improve understanding of how currently
available physiological and imaging tests reﬂect small airway
disease in different locations of the bronchial tree, and may
identify new small airway disease subtypes with possible clinical
relevance in the context of treatment such as biologicals. The
ongoing discussion of proving the added value of extra-ﬁne
particles, and a range of particle sizes in an administration, could
also proﬁt from this new technique. n
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Stratifying Bronchiectasis: Getting to within a Zone’s Throw
Bronchiectasis is a chronic, progressive, and irreversible dilatation
of the airway that exhibits geographic variation, contrasting
endophenotypes, and involvement in “overlap” states (1–4). Its
clinical heterogeneity and etiological complexity are compounded
by our incomplete understanding of its pathogenesis. This leads to
difﬁculties with clinical trials and therefore a lack of evidence-based
treatments for patients (5).
The archetype “Cole’s vicious cycle” model of pathogenesis
has formed the basis for emerging concepts such as the “vicious
vortex,” which offers a more holistic view of the disease, reafﬁrming
its key interrelated components: infection, inﬂammation, epithelial-
immune dysfunction, and lung destruction (6, 7). All of these
components interact and are inﬂuenced by one another, perhaps
to different extents, in different patients and etiologies and at
various disease severities, including exacerbations. Consequently,
improving patient stratiﬁcation and identifying “high-risk” bronchiectasis
endophenotypes are key focuses of ongoing research (5, 8).
Although airway infection incites and propagates disease, the
immune–inﬂammatory consequences (even in the absence of
infection) have a strong inﬂuence on disease outcomes. Neutrophils
in particular are the hallmark airway inﬂammatory cells and a source
of protection against infection, but when excessive in number and
response, they can induce further airway damage and bronchiectasis.
Neutrophils have important roles in severe asthma, chronic
obstructive pulmonary disease (COPD), and cystic ﬁbrosis (CF),
where airway-dominant phenotypes are associated with poor disease
outcomes. Airway and systemic neutrophils are dysfunctional in
bronchiectasis, and although immune dysregulation is a recognized
feature in disease, the mechanisms by which neutrophilic
inﬂammation is linked to impaired immunity, particularly in the
context of infection, remain poorly understood (1, 5, 9, 10). This is
exempliﬁed by the paradoxical strong, cellular-abundant, and
sustained neutrophilic response observed with persistence of airway
infection. Acute infections in bronchiectasis are cleared by
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